Before you sell to, join or invest in Indaptus Therapeutics, Inc.
MentionFox check on Indaptus Therapeutics, Inc.: no red flags found in 4 sources (checked 8 November 2026). mentionfox.com/c/funding/indaptus-therapeutics-inc-form-d-24000001
Check Indaptus Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Indaptus Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2024-12-06.
Indaptus Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 6, 2024. The filing reports $227K sold. Its industry group is Pharmaceuticals. It names JEFFREY MECKLER (Executive Officer, Director), WALT LINSCOTT (Executive Officer), NIR SASSI (Executive Officer) (SEC Form D, December 6, 2024).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Indaptus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-12-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Indaptus Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Indaptus Therapeutics, Inc., from the filings we hold.
Paulson Investment Company, LLC received sales compensation on this raise and on 8 other raises we hold, nearest in date first:
Get an email when Indaptus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Indaptus Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Indaptus Therapeutics, Inc. →Get the full cited report on Indaptus Therapeutics, Inc.
What the filing shows about Indaptus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Indaptus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Indaptus Therapeutics, Inc.'s address as 3 Columbus Circle, 15TH Floor, New York, NY 10019.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Indaptus Therapeutics, Inc. See pricing
Indaptus Therapeutics, Inc. is a registered filer with the SEC (CIK 1857044) and has filed since 2024-08-22. 5 filings are on record, the latest on 2025-06-20.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Indaptus Therapeutics, Inc.'s Form D of 2024-12-06 names JEFFREY MECKLER, WALT LINSCOTT, NIR SASSI and 8 more as its officers, directors or promoters.
Its new offerings report $4.99M sold across 4 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Issuer expects to use proceeds from the offering to fund its research and development activities and for working capital and general corporate purposes.
Jeffrey Meckler is named as Executive Officer and Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Walt Linscott is named as Executive Officer on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Nir Sassi is named as Executive Officer on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Michael Newman is named as Executive Officer and Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Roger Waltzman is named as Executive Officer on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Hila Karah is named as Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Anthony Maddaluna is named as Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
William Hayes is named as Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Roger Pomerantz is named as Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Mark Gilbert is named as Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
Robert Martell is named as Director on the Form D that Indaptus Therapeutics, Inc. filed with the SEC on 6 December 2024, one of 11 people that filing names.
11 people named on the filing — 5 holding an executive role and 6 as directors only.
Named as of the 2024-12-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Indaptus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Indaptus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Indaptus Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Indaptus Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Indaptus Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Indaptus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in New York
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/indaptus-therapeutics-inc-form-d-24000001